CLOs on the Move

Radioisotope Life Sciences

www.rls.bio

 
RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.rls.bio
  • 801 International Parkway Suite 5092
    Lake Mary, FL USA 32746
  • Phone: 813.285.3065

Executives

Name Title Contact Details
Glenn Sullivan
Director of Regulatory Affairs Profile

Similar Companies

Talkiatry

Launched in April 2020, Talkiatry provides accessible in-network psychiatric care. The technology-driven service is committed to providing the highest level of mental health care on an outpatient basis. Based in New York City, Talkiatry offers seamless telehealth as well as in-person care in thoughtfully-designed, upscale offices—all at affordable, in-network prices. Talkiatry accepts a wide-range of insurance and employs psychiatrists and psychiatric nurse practitioners curated from among the city`s finest healthcare providers.

Comfort Medical

You will find the best source for major brands and most types of catheter and ostomy supplies at Comfort Medical. Free Home Delivery 800-700-4246

Rehab 2 Perform

R2P creates a unique physical therapy experience, offering our blend of performance, return to sport, physical therapy, dry needling and injury prevention.

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.